88329 20210121114533.0 doi 10.1210/jc.2014-4409 sideral 90412 ART-2015-90412 eng Ledesma, Marta Association of ferritin elevation and metabolic syndrome in males. Results from the Aragon Workers' Health Study (AWHS) 2015 Access copy available to the general public Unrestricted Context: Ferritin concentration is associated with metabolic syndrome, but the possibility of a nonlinear association has never been explored. Objective: This study aimed to examine the relationship between serum ferritin levels and the metabolic syndrome in Spanish adult males. Design: This was a cross-sectional analysis of baseline data from the Aragon Workers' Health Study. Setting: Healthy workers from a factory were studied during their annual checkup. Participants: Spanish male adults (n = 3386) between the ages of 19 and 65 years participated. We excluded participants with ferritin > 500 µg/L, ferritin < 12 µg/L, or C-reactive protein > 10 mg/L. Main Outcome Measure: Metabolic syndrome was defined according to the 2009 consensus definition from the Joint Interim Statement of several international societies. Results: Metabolic syndrome prevalence was 27.1%. We found a positive association between elevated iron stores, measured as serum ferritin concentration, and metabolic syndrome and its criteria. Participants within the highest serum ferritin quintile had a higher risk than those in the lowest quintile for central obesity (odds ratio [OR], 1.88; 95% confidence interval [CI], 1.46–2.42), hypertriglyceridemia (OR, 2.15; 95% CI, 1.69–2.74), and metabolic syndrome (OR, 1.92; 95% CI, 1.48–2.49). The association was nonlinear and occurred at serum ferritin concentrations > 100 µg/L (~ 33th percentile). Ferritin was also associated with insulin resistance, measured by homeostatic model assessment–insulin resistance (HOMA-IR) (P trend < .001). Conclusions: Our findings suggest that serum ferritin is significantly associated with metabolic syndrome and its criteria (especially central obesity and hypertriglyceridemia), suggesting that ferritin could be an early marker of metabolic damage in the development of metabolic syndrome. info:eu-repo/grantAgreement/ES/FIS/PI10-00021 info:eu-repo/grantAgreement/ES/ISCIII-FIS/CP08-00112 info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI12-01434 info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI14-00009 info:eu-repo/grantAgreement/ES/ISCIII/PI12-01703 info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 5.531 2015 ENDOCRINOLOGY & METABOLISM 16 / 131 = 0.122 2015 Q1 T1 3.071 2015 Biochemistry 2015 Q1 Biochemistry (medical) 2015 Q1 Medicine (miscellaneous) 2015 Q1 Endocrinology 2015 Q1 Endocrinology, Diabetes and Metabolism 2015 Q1 Clinical Biochemistry 2015 Q1 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Hurtado-Roca, Yamilee Leon, Montserrat (orcid)0000-0002-8791-1901 Giraldo, Pilar (orcid)0000-0001-8807-9187 Pocovi, Miguel Universidad de Zaragoza (orcid)0000-0001-7043-0952 Civeira, Fernando Universidad de Zaragoza Guallar, Eliseo Ordovas, José María (orcid)0000-0002-9887-2629 Casasnovas, José Antonio. Universidad de Zaragoza (orcid)0000-0003-3963-0846 Laclaustra, Martín 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 1002 060 Universidad de Zaragoza Dpto. Bioq.Biolog.Mol. Celular Área Bioquímica y Biolog.Mole. 100, 5 (2015), 2081-2089 J. clin. endocrinol. metab. The journal of clinical endocrinology and metabolism 0021-972X 190890 http://zaguan.unizar.es/record/88329/files/texto_completo.pdf Versión publicada 31367 http://zaguan.unizar.es/record/88329/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:88329 articulos driver 2021-01-21-11:12:03 ARTICLE